In this issue:
EVEREST: Adjuvant everolimus beneficial only in very-high risk RCC
Front-line pembrolizumab + lenvatinib has durable activity in non-clear cell RCC
Tivozanib has promising anti-tumour activity in non-clear cell RCC
High burden of CVD in testicular cancer survivors
Longitudinal ctDNA analysis to monitor genitourinary tumour response to ICI
Morbidity of elective surgery for localised renal masses among elderly patients
Chemoradiotherapy promising for locoregionally advanced penile carcinoma
Nivolumab/cabozantinib more effective than pembrolizumab/axitinib in RCC
High rate of complications after RPLND for testicular cancer
Robot-assisted RPLND feasible for metastatic germ cell tumours
Please login below to download this issue (PDF)